The trial prospectively examined three potential biomarkers of PARP inhibitor activity, a molecular signature of HR deficiency using HRDetect, RAD51 focus formation in a tumor biopsy at the end of treatment, and BRCA1 methylation. Here, PARP1 is linked to neoplasm.